Free Trial

More results...

Filter by Content types
Regulatory databases
Regulatory reports
Market reports
News analysis
Filter by Geography
Africa
Asia
Australasia
Europe
United Kingdom
North America
United States
South America

Alerts LATEST ALERTS

  • Italy Hemp industry takes legal action against national hemp ban ...
  • Spain HHC and other cannabinoids listed as Schedule II drugs ...
  • Germany AfD slams coalition for omitting cannabis recriminalisation plan ...
  • Arkansas - United States Bill regulating hemp-derived products signed into law ...
  • Chile Bill proposes legalising adult use of cannabis ...
  • North Dakota - United States Bill to restrict medical cannabis edibles becomes law ...
  • Germany BfArM and medical groups call for more cannabis regulation to prevent abuse ...
  • Indiana - United States Bill that would regulate hemp products passes and awaits governor’s signature ...
  • Italy Italian MEPs question if an Italian law on hemp flower conflicts with EU law ...
  • Maryland - United States Governor signs cannabis bill into law ...
  • Alabama - United States Injunction issued again medical cannabis licences ...
  • Belgium FPS updates positive list of herbal product notifications ...
News analysis

UK company raises £7.4m for medicinal cannabis research

Written by || 15th January 2019 || News analysis | Companies | Technology and innovation | GeographiesEngland Europe United Kingdom

A British biopharmaceutical company will be trialling the use of CBD and other hemp-based products for treating opioid addiction, as well as other conditions.

Beckley Canopy Therapeutics has raised £7.4m to carry out research into the use of various extracts from the cannabis plant in order to develop medicines for people suffering cancer-related pain. In comparison, the US  National Center for Complementary and Integrative Health (NCCIH) has said it would spend up to $1.5m to fund research on minor cannabinoids and terpenes in the cannabis plant as it relates to responses to pain.

It is also hoped that any new treatments will be used to help reduce the use of opioid-based painkillers – a possible application of CBD in which there is already a great deal of interest.

Read full article

Download the full news analysis

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

I'm already a subscriber
Author default picture

CannIntelligence

This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Thanks for getting in touch with us

Please leave your enquiry and we will get back to you within 24 hours

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key market trends and regulatory news and receive complimentary data on a regular basis.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.